These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 33240257)

  • 41. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.
    Modjarrad K; Roberts CC; Mills KT; Castellano AR; Paolino K; Muthumani K; Reuschel EL; Robb ML; Racine T; Oh MD; Lamarre C; Zaidi FI; Boyer J; Kudchodkar SB; Jeong M; Darden JM; Park YK; Scott PT; Remigio C; Parikh AP; Wise MC; Patel A; Duperret EK; Kim KY; Choi H; White S; Bagarazzi M; May JM; Kane D; Lee H; Kobinger G; Michael NL; Weiner DB; Thomas SJ; Maslow JN
    Lancet Infect Dis; 2019 Sep; 19(9):1013-1022. PubMed ID: 31351922
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TBE booster immunization in adults--first experience with a new tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer.
    Zent O; Schwarz TF; Plentz A; Banzhoff A; Jilg W
    Int J Med Microbiol; 2004 Apr; 293 Suppl 37():134-8. PubMed ID: 15146995
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
    Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
    Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Field study of the safety, immunogenicity, and efficacy of an inactivated equine rotavirus vaccine.
    Powell DG; Dwyer RM; Traub-Dargatz JL; Fulker RH; Whalen JW; Srinivasappa J; Acree WM; Chu HJ
    J Am Vet Med Assoc; 1997 Jul; 211(2):193-8. PubMed ID: 9227750
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibody Persistence up to 3 Years After Primary Immunization With Inactivated Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a Booster Dose.
    Kadlecek V; Borja-Tabora CF; Eder-Lingelbach S; Gatchalian S; Kiermayr S; Sablan B; Kundi M; Taucher C; Dubischar KL
    Pediatr Infect Dis J; 2018 Sep; 37(9):e233-e240. PubMed ID: 29912844
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
    Treanor JT; Albano FR; Sawlwin DC; Graves Jones A; Airey J; Formica N; Matassa V; Leong J
    Vaccine; 2017 Apr; 35(15):1856-1864. PubMed ID: 28302411
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Safety and immunogenicity of inactivated bivalent EHF vaccine in humans].
    Liu W; Xu X; Ruan Y; Weng S; Liu W; Zhou W; Dong G; Gu H; Zhu Z; Xu Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 2000 Dec; 21(6):445-7. PubMed ID: 11860832
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine.
    Montalban C; Montellano MB; Santos J; Lavis N
    Hum Vaccin Immunother; 2018 Mar; 14(3):593-595. PubMed ID: 28933626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity, safety, and tolerability of two trivalent subunit inactivated influenza vaccines: a phase III, observer-blind, randomized, controlled multicenter study.
    Tregnaghi MW; Stamboulian D; Vanadía PC; Tregnaghi JP; Calvari M; Fragapane E; Casula D; Pellegrini M; Groth N
    Viral Immunol; 2012 Jun; 25(3):216-25. PubMed ID: 22691101
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.
    Rouphael NG; Paine M; Mosley R; Henry S; McAllister DV; Kalluri H; Pewin W; Frew PM; Yu T; Thornburg NJ; Kabbani S; Lai L; Vassilieva EV; Skountzou I; Compans RW; Mulligan MJ; Prausnitz MR;
    Lancet; 2017 Aug; 390(10095):649-658. PubMed ID: 28666680
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial.
    Cheng A; Hsieh SM; Pan SC; Li YH; Hsieh EF; Lee HC; Lin TW; Lai KL; Chen C; Shi-Chung Chang S; Chang SC
    J Microbiol Immunol Infect; 2019 Oct; 52(5):685-692. PubMed ID: 31255574
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women.
    Munoz FM; Jackson LA; Swamy GK; Edwards KM; Frey SE; Stephens I; Ault K; Winokur P; Petrie CR; Wolff M; Patel SM; Keitel WA
    Vaccine; 2018 Dec; 36(52):8054-8061. PubMed ID: 30416018
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparable immune responsiveness but increased reactogenicity after subcutaneous versus intramuscular administration of tick borne encephalitis (TBE) vaccine.
    Hopf S; Garner-Spitzer E; Hofer M; Kundi M; Wiedermann U
    Vaccine; 2016 Apr; 34(17):2027-34. PubMed ID: 26768126
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
    Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S
    Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serologic responses to eastern and western equine encephalomyelitis vaccination in previously vaccinated horses.
    Waldridge BM; Wenzel JG; Ellis AC; Rowe-Morton SE; Bridges ER; D'Andrea G; Wint R
    Vet Ther; 2003; 4(3):242-8. PubMed ID: 15136985
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation.
    Hannaman D; Dupuy LC; Ellefsen B; Schmaljohn CS
    Vaccine; 2016 Jun; 34(31):3607-12. PubMed ID: 27206386
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants.
    Klein NP; Abu-Elyazeed R; Cornish M; Leonardi ML; Weiner LB; Silas PE; Grogg SE; Varman M; Frenck RW; Cheuvart B; Baine Y; Miller JM; Leyssen M; Mesaros N; Roy-Ghanta S
    Vaccine; 2017 Jun; 35(28):3564-3574. PubMed ID: 28536030
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: using PRNT50 as an endpoint for immunogenicity.
    Reisler RB; Danner DK; Gibbs PH
    Vaccine; 2010 Mar; 28(12):2436-41. PubMed ID: 20060946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.